TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8822160

Group type: EXPERIMENTAL
Intervention: Blocking the visuospatial sketchpad (by manipulation of a keypad)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocking the central executive (by random letter generation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial secondary task (random generation of keypresses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal secondary task (vocal generation of random numbers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 2248740

Group type: EXPERIMENTAL
Intervention: Combination of antibiotics (amoxicillin) and oral steroids (prednisone)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 7358200

Group type: EXPERIMENTAL
Intervention: Loxapine (10-150 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thioridazine (150-750 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both Loxapine and Thioridazine
Number of subjects: 0
Study: 31787001

Group type: EXPERIMENTAL
Intervention: Repair of pronator quadratus muscle
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-repair of pronator quadratus muscle
Number of subjects: 72
Study: 27664232

Group type: EXPERIMENTAL
Intervention: Cardiogoniometry
Number of subjects: 114

Group type: COMPARATOR
Intervention: Exercise‐ECG test
Number of subjects: 114
Study: 26216164

Group type: EXPERIMENTAL
Intervention: Group Cognitive‐Behavioral Therapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 43
Study: 23893527

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 20940383

Group type: EXPERIMENTAL
Intervention: Buprenorphine implants (4 implants, 80 mg each)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo implants (4 implants)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Buprenorphine implants
Number of subjects: 163
Study: 18426577

Group type: EXPERIMENTAL
Intervention: Relora (250 mg capsules, 3 times daily for 6 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Relora
Number of subjects: 40
Study: 16629006

Group type: EXPERIMENTAL
Intervention: Intervention to increase use of hearing protection devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transtheoretical model framework
Number of subjects: 0
Study: 14582585

Group type: EXPERIMENTAL
Intervention: Triclosan-containing dental gel (0.3%) applied for 5 min twice daily for 14 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 14
Study: 10757567

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oxycodone-thiopental
Number of subjects: 30
Study: 8699068

Group type: EXPERIMENTAL
Intervention: SPf66 synthetic vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2021589

Group type: EXPERIMENTAL
Intervention: Phenylephrine drops (10%) with modified dropper tip (smaller volume)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenylephrine drops (10%) with normal dropper tip (normal volume)
Number of subjects: 0
Study: 7129028

Group type: EXPERIMENTAL
Intervention: Labyrinthine stimulation (ear irrigation with ice water)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control stimulation (ear irrigation at 37 degrees C)
Number of subjects: 4

Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Labyrinthine stimulation
Number of subjects: 4
Study: 30590833

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg s.c. every 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg s.c. every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tocilizumab 4 mg/kg i.v. every 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tocilizumab 8 mg/kg i.v. (if clinically indicated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sarilumab and Tocilizumab (both studies)
Number of subjects: 0
Study: 29087903

Group type: EXPERIMENTAL
Intervention: MARP plus home neuromuscular electrical stimulation therapy (n = 23)
Number of subjects: 44

Group type: COMPARATOR
Intervention: MARP alone (n = 21)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combined rehabilitation cohort
Number of subjects: 44
Study: 25773566

Group type: EXPERIMENTAL
Intervention: Clinical chronic obstructive pulmonary disease questionnaire (CCQ)
Number of subjects: 0
Study: 24610309

Group type: EXPERIMENTAL
Intervention: Revascularization (PCI/CABG)
Number of subjects: 39131
Study: 23618054

Group type: EXPERIMENTAL
Intervention: Educational policing strategy (letters, incident reports, covert audits, feedback meetings)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Educational policing strategy (intensive police response)
Number of subjects: 21
Study: 19941765

Group type: EXPERIMENTAL
Intervention: Indirect pulp treatment (IPT) with calcium hydroxide (CH) or gutta‐percha (GP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Positive control group (sound molars)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Negative control group (carious teeth)
Number of subjects: 18
Study: 17599568

Group type: EXPERIMENTAL
Intervention: Unaltered prosthesis head size
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Reduced prosthesis head size
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Augmented prosthesis head size
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison of all three head sizes (unaltered, reduced, augmented)
Number of subjects: 9
Study: 15366589

Group type: EXPERIMENTAL
Intervention: Huannao Yicong capsule (HYC) 3 capsules, 3 times daily for 2 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Hydergin 3 tablets, 3 times daily for 2 months
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Huannao Yicong capsule (HYC)
Number of subjects: 62
Study: 11329558

Group type: EXPERIMENTAL
Intervention: Training from a standardized patient
Number of subjects: 98

Group type: COMPARATOR
Intervention: Lecture/demonstration class
Number of subjects: 98
Study: 10024707

Group type: EXPERIMENTAL
Intervention: Active treatment (ear electroacupuncture with two needles at an active site and self-retained ear seeds for two weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo treatment (ear electroacupuncture with two needles at a placebo site and self-retained ear seeds for two weeks)
Number of subjects: 78
Study: 7981930

Group type: EXPERIMENTAL
Intervention: Colestipol (10 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cholestyramine (8 g)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water only (control)
Number of subjects: 6
Study: 3054010

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 31632269

Group type: EXPERIMENTAL
Intervention: Pidotimod 800 mg b/d for 21 consecutive days per month for 6 months (V1 group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No drug (V0 group)
Number of subjects: 40
Study: 28860174

Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure (LBNP; -10 mmHg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lower-body positive pressure (LBPP; +10 mmHg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High altitude (HA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sea level (SL)
Number of subjects: 14
Study: 26212437

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) treatment
Number of subjects: 69

Group type: COMPARATOR
Intervention: Virological response (patients with ETV treatment)
Number of subjects: 69
Study: 23199101

Group type: EXPERIMENTAL
Intervention: Total arch distalization using orthodontic mini‐implants (OMIs) combined with interproximal stripping (IPS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Second premolar extraction
Number of subjects: 66
Study: 21889262

Group type: EXPERIMENTAL
Intervention: Nitrous oxide anesthesia
Number of subjects: 640
Study: 18835404

Group type: EXPERIMENTAL
Intervention: Two-year multi-component program including classroom activities, development of school Travel Access Guides, parent newsletters, and improving environments with local councils
Number of subjects: 1996

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1996
Study: 16482236

Group type: EXPERIMENTAL
Intervention: Low-volume PEG plus sennosides (120 mg oral sennosides syrup followed by 2 L PEG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard volume PEG (4 L PEG)
Number of subjects: 0
Study: 12908830

Group type: EXPERIMENTAL
Intervention: Risperidone (atypical antipsychotic medication)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 2
Study: 10983914

Group type: EXPERIMENTAL
Intervention: Alendronate (Fosamax)
Number of subjects: 6459

Group type: EXPERIMENTAL
Intervention: Fair-to-poor self-rated health
Number of subjects: 6459

Group type: EXPERIMENTAL
Intervention: Four or more depressive symptoms
Number of subjects: 6459

Group type: EXPERIMENTAL
Intervention: Good self-rated health
Number of subjects: 6459
Study: 9498151

Group type: EXPERIMENTAL
Intervention: Nadroparin calcium (Fraxoparine Sanofi France)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 100
Study: 8149110

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (45 mg/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 3775603

Group type: EXPERIMENTAL
Intervention: No serum (group 1)
Number of subjects: 53

Group type: COMPARATOR
Intervention: 10% patient's serum (group 2)
Number of subjects: 53
Study: 29439085

Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study: 26471280

Group type: EXPERIMENTAL
Intervention: Intervention group with printed symptom summaries available before each weekly office visit
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group without printed symptom summaries
Number of subjects: 112
Study: 23413812

Group type: EXPERIMENTAL
Intervention: Titanium-zirconium alloy narrow diameter implants
Number of subjects: 42

Group type: COMPARATOR
Intervention: Commercially pure titanium narrow diameter implants
Number of subjects: 42
Study: 21942405

Group type: EXPERIMENTAL
Intervention: Resource-building group intervention workshops
Number of subjects: 718

Group type: COMPARATOR
Intervention: Printed information about career and health-related issues (comparison group)
Number of subjects: 718
Study: 20234292

Group type: EXPERIMENTAL
Intervention: Nurse case management (average of 60 min of case management time per month)
Number of subjects: 1551
Study: 17606955

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg/d)
Number of subjects: 3809

Group type: COMPARATOR
Intervention: Low-dose atorvastatin (10 mg/d)
Number of subjects: 3809
Study: 15617697

Group type: EXPERIMENTAL
Intervention: Ritodrine tocolysis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: External cephalic version
Number of subjects: 60
Study: 11907389

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg intravenous)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study: 10459409

Group type: EXPERIMENTAL
Intervention: AMPT (alpha-methyl-para-tyrosine)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (diphenhydramine hydrochloride)
Number of subjects: 6
Study: 7887644

Group type: EXPERIMENTAL
Intervention: Arm A: 250 mg/m2 of l‐LV and 600 mg/m2 of 5‐FU weekly
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Arm B: 100 mg/m2 of l‐LV and 370 mg/m2 of 5‐FU for 5 consecutive days
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Arm C: 10 mg/m2 of l‐LV and 370 mg/m2 of 5‐FU for 5 consecutive days
Number of subjects: 73
Study: 2403824

Group type: EXPERIMENTAL
Intervention: Native prothrombin antigen (therapeutic range, 12 to 24 micrograms/mL)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Prothrombin time index (therapeutic range, 1.5 to 2.0)
Number of subjects: 156
Study: 240140

Group type: EXPERIMENTAL
Intervention: Alclofenac 500 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin 25 mg
Number of subjects: 0
Study: 31665476

Group type: EXPERIMENTAL
Intervention: High water (HW) intake targeting urine osmolality (UOsm) ≤270 mOsm/kg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High water (HW) intake
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ad libitum (AW) intake
Number of subjects: 42
Study: 30611157

Group type: EXPERIMENTAL
Intervention: Graduates of pediatric neurosurgery fellowship programs
Number of subjects: 391
Study: 29202730

Group type: EXPERIMENTAL
Intervention: Biomarker-guided antibiotic treatment of stroke associated pneumonia
Number of subjects: 229

Group type: COMPARATOR
Intervention: Patients able to consent
Number of subjects: 229
Study: 25911711

Group type: EXPERIMENTAL
Intervention: Sonographic diagnosis for contralateral malignancy
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Sonographic classes IV and V (possibly malignant and malignant)
Number of subjects: 143
Study: 23707824

Group type: EXPERIMENTAL
Intervention: Internet counseling (daily e-mails with recommended activities through Pfizer's GetQuit program)
Number of subjects: 217

Group type: COMPARATOR
Intervention: In-person counseling (four 1.5 hour classes based on the American Cancer Society's Freshstart program)
Number of subjects: 217
Study: 22189150

Group type: EXPERIMENTAL
Intervention: Once-daily darunavir/ritonavir (DRV/r) 800/100 mg
Number of subjects: 343

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir 800/200 mg
Number of subjects: 343
Study: 18423977

Group type: EXPERIMENTAL
Intervention: Suspicious DRE
Number of subjects: 5040

Group type: COMPARATOR
Intervention: Normal DRE
Number of subjects: 5040
Study: 17203523

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment (Shehuang Paste + Chinese herbal colon dialysis)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Simple treatment (Shehuang Paste only)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (basic treatment only)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Simple treatment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study: 14598412

Group type: EXPERIMENTAL
Intervention: Minilaparoscopic cholecystectomy (MLC)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Traditional laparoscopic cholecystectomy (LC)
Number of subjects: 135
Study: 11998122

Group type: EXPERIMENTAL
Intervention: Telephone follow-ups
Number of subjects: 0
Study: 8810951

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Catheter lavage (CL)
Number of subjects: 66
Study: 1454836

Group type: EXPERIMENTAL
Intervention: Tacrine at a dose of 80 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6360815

Group type: EXPERIMENTAL
Intervention: Propranolol (non‐selective beta 1 and beta 2 blocker)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prazosin (alpha blocker)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atenolol (selective beta 1 blocker)
Number of subjects: 24
Study: 31583918

Group type: EXPERIMENTAL
Intervention: Norwegian Anterior Knee Pain Scale (AKPS)
Number of subjects: 112
Study: 31153977

Group type: EXPERIMENTAL
Intervention: Financial incentive with several contact approaches
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (using the same contact approaches)
Number of subjects: 129
Study: 28731883

Group type: EXPERIMENTAL
Intervention: Cancer PEPSONE Program (CPP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 27636923

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) cycle in addition to standard therapy for COPD
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard COPD treatment only
Number of subjects: 70
Study: 24586896

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group (dietary advice, coaching, and exercise)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Children from the RCT
Number of subjects: 301

Group type: COMPARATOR
Intervention: Reference group children (born to women with normal BMI)
Number of subjects: 301
Study: 23306857

Group type: EXPERIMENTAL
Intervention: etched GMTA (EGMTA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: gray-colored MTA (GMTA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: etched WMTA (EWMTA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: white-colored MTA (WMTA)
Number of subjects: 64
Study: 19959772

Group type: EXPERIMENTAL
Intervention: Voxel-based DTI analysis in mTBI patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control participants (age-matched)
Number of subjects: 10
Study: 16548702

Group type: EXPERIMENTAL
Intervention: Providing a 'risk anchor' based on downward social comparison processes
Number of subjects: 134

Group type: COMPARATOR
Intervention: Public commitment, self-consistency, unique causal risk models
Number of subjects: 134

Group type: COMPARATOR
Intervention: Pessimism and differences in understanding percentages
Number of subjects: 134
Study: 12656871

Group type: EXPERIMENTAL
Intervention: Bio-Gide membrane (Group A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bio-Oss (Group B)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Spontaneous healing (Group C)
Number of subjects: 21
Study: 11191543

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human IL-12 (0.1, 0.25, 0.5 microg/kg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 9663842

Group type: EXPERIMENTAL
Intervention: Ranitidine effervescent tablets 150 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ranitidine effervescent tablets 300 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Famotidine fast-dissolving tablets 20 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Omeprazole capsules 20 mg
Number of subjects: 15
Study: 1553114

Group type: EXPERIMENTAL
Intervention: Creon
Number of subjects: 27

Group type: COMPARATOR
Intervention: Pancrease
Number of subjects: 27
Study: 2952668

Group type: EXPERIMENTAL
Intervention: Prednisolone, 7.5 mg daily for one cycle in addition to Clomid and/or gonadotrophins
Number of subjects: 73

Group type: COMPARATOR
Intervention: Non-prednisolone group (control)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Prednisolone group
Number of subjects: 73
Study: 31378155

Group type: EXPERIMENTAL
Intervention: Exposure to video news stories and print articles on child safety topics
Number of subjects: 1081
Study: 29861224

Group type: EXPERIMENTAL
Intervention: Tactile-kinesthetic stimulation (TKS) performed by mothers, 15 minutes, two times a day for at least 28 consecutive days.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 60
Study: 27189295

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg) for 5 minutes
Number of subjects: 74

Group type: COMPARATOR
Intervention: Remifentanil with an effect site concentration of 1.5 ng/mL until endotracheal extubation
Number of subjects: 74
Study: 25213871

Group type: EXPERIMENTAL
Intervention: NovoTTF-100A System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best physician's choice (BPC) chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NovoTTF-100A System with compliance ≥75%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NovoTTF-100A System with compliance <75%
Number of subjects: 0
Study: 22700854

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 4591

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 4591

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4591

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg (urgent surgery)
Number of subjects: 4591

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg (urgent surgery)
Number of subjects: 4591

Group type: COMPARATOR
Intervention: Warfarin (urgent surgery)
Number of subjects: 4591
Study: 20473184

Group type: EXPERIMENTAL
Intervention: Efavirenz arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lopinavir arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Model prediction
Number of subjects: 0
Study: 17619534

Group type: EXPERIMENTAL
Intervention: LAM monotherapy (100 mg/day, PO, for 24 months)
Number of subjects: 45

Group type: COMPARATOR
Intervention: LAM plus IFN-alpha combination therapy (IFN-alpha-2b, 10 MU, tiw, SC, for 6 months plus LAM 100 mg/day, PO, for 24 months)
Number of subjects: 45
Study: 17140102

Group type: EXPERIMENTAL
Intervention: Gene and cell therapy aimed at stimulating angiogenesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prostanoids, spinal cord stimulation, and lumbar sympathectomy
Number of subjects: 0
Study: 15013271

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Non-users of oral contraceptives
Number of subjects: 219
Study: 10746839

Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 8931610

Group type: EXPERIMENTAL
Intervention: Radiation therapy (n = 416)
Number of subjects: 837

Group type: COMPARATOR
Intervention: No radiation therapy (n = 421)
Number of subjects: 837
Study: 1347803

Group type: EXPERIMENTAL
Intervention: 3000 U r‐HuEPO
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 6000 U r‐HuEPO
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 9000 U r‐HuEPO
Number of subjects: 25

Group type: COMPARATOR
Intervention: No r‐HuEPO (control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (all doses)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: r‐HuEPO
Number of subjects: 25
Study: 3887076

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of lidocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20